Femara, Letrozole News

The combination of two drugs -- Femara and follicle-stimulating hormone -- could be of benefit in infertile women of advanced reproductive age undergoing intrauterine insemination, results of a study indicate.

ROCKVILLE,A Md. The Food and Drug Administration has given tentative approval to a generic drug for treating breast cancer.

The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Oral presentation on Sandostatin LAR Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut * Early data show that at eight weeks of ...

There are several infertility treatment methods that people can opt when the should face the miserable truth that they are affected by infertility.

RDATE:03022009 Dublin - Research and Markets has announced the addition of the "Novartis: Performance - Products - Pipeline - Potential" companyprofile to their offering.

FIVE hundred Dorset women a year could benefit from a new drug that reduces the risk of breast cancer coming back in older women who have been treated for the disease.

New results from a study in metastatic breast cancer presented today at the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium showed that the combination of Tykerb plus letrozole, as a first line ...

Combining GlaxoSmithKline's Tykerb drug with Novartis's Femara can delay significantly the progression of breast cancer in some women, researchers said on Thursday.

Femara showed reduced risk of death by 13% versus tamoxifen, despite inclusion of patients who had switched over from tamoxifen to Femara during the study period, following the study's unblinding - In a ...

New research adds fresh hope that a drug that strengthens bones might also fight breast cancer.

New results from a study evaluated the combination of TYKERB plus Femara versus letrozole alone as a first-line treatment regimen in hormone receptor positive metastatic breast cancer.

11 /CNW Telbec/ - New long-term data from a major international breast cancer study demonstrates that treatment with Femara may provide an important survival benefit compared to treatment with tamoxifen in ...

EAST HANOVER, N.J., Dec 04, 2008 /PRNewswire via COMTEX/ -- - Tasigna front-line data demonstrating potential in newly diagnosed patients with a life-threatening type of leukemia to be featured in two oral ...

Details of the settlement are confidential, but Mylan stated it will market a generic version of Femara before the patent expires.

Mylan Pharmaceuticals Inc., a subsidiary of Mylan Inc. , said Tuesday it has settled with Novartis Pharmaceuticals Corp, Novartis Corp.